225430 — KMPharmaceutical Co Balance Sheet
0.000.00%
- KR₩25bn
- KR₩37bn
- KR₩18bn
Annual balance sheet for KMPharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Interim Report | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,493 | 5,879 | 2,697 | 598 | 1,024 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,365 | 2,836 | 3,753 | 2,281 | 2,334 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7,430 | 12,107 | 9,846 | 6,345 | 5,982 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 24,750 | 26,963 | 25,009 | 22,325 | 21,183 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 43,143 | 50,240 | 52,676 | 51,281 | 50,555 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,342 | 3,108 | 7,473 | 12,498 | 11,882 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 18,948 | 9,466 | 12,770 | 14,953 | 15,077 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 24,194 | 40,774 | 39,906 | 36,328 | 35,479 |
Total Liabilities & Shareholders' Equity | 43,143 | 50,240 | 52,676 | 51,281 | 50,555 |
Total Common Shares Outstanding |